期刊文献+

他汀类药物作用机制及其在卒中防治中的应用 被引量:8

The Acting Mechanisms of Statins and Their Application in the Prevention and Treatment of Stroke
原文传递
导出
摘要 在世界范围内卒中是最重要的致残病因之一。流行病学和临床研究显示,他汀类药物可显著降低缺血性卒中的发病率。除降脂效应外,他汀类药物还存在不依赖于降低胆固醇水平的其他许多作用机制。另外,他汀类药物可抑制蛛网膜下腔出血引起的脑血管痉挛。对于大多数个体来说,他汀类药物的安全性和耐受性良好。 Stroke is one of the most important causes of disability throughout the world. Epidemiological and clinical studies have demonstrated that statins significantly decrease the incidence of ischemic stroke. In addition to lipid-lowering effect, statins may also have a number of other acting mechanisms that are not dependent on reducing cholesterol levels. Moreover, statins inhibit cerebral vasospasm caused by subarachnoid hemorrhage. For most of the individuals, the safety and tolerability of statins are well.
出处 《国际脑血管病杂志》 2007年第10期757-761,共5页 International Journal of Cerebrovascular Diseases
基金 国家自然科学基金(No30570656)
关键词 他汀类药物 卒中 蛛网膜下腔出血 脑血管痉挛 statins stroke subarachnoid hemorrhage cerebral vasospasm
  • 相关文献

参考文献23

  • 1Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J, 2006, 151 : 273 -281.
  • 2Miida T, Himyama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb, 2004, 11 : 253 - 264.
  • 3Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest, 2002, 109:1125 - 1131.
  • 4Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis--as good as it gets? N Engl J Med, 2005, 352 : 73 - 75.
  • 5Morgan AR, Rerkasem K, Gallagher P J, et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke, 2004, 35:1310 - 1315.
  • 6Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation, 2001, 103 : 2885 - 2890.
  • 7Nordφy A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost, 2003, 1 : 690 - 697.
  • 8Jaeobson JR, Dudek SM, Birukov KG, et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol, 2004, 30:662 -670.
  • 9Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 2007, 115:459 -467.
  • 10Watanabe K, Sugiyama S, Kugiyama K, et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coil Cardiol, 2005, 46:2022 -2030.

同被引文献85

引证文献8

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部